Discloure Notice

Disclosure Notice Stockholm, February 11, 2004 Investor's share of the voting rights and share capital in AstraZeneca has changed through the divestment of 21,200,000 shares. After the sale, Investor's holding in AstraZeneca now amounts to 63,465,810 shares corresponding to 3.75 percent of the voting rights and share capital. On December 31, 2003, Investor's holding in AstraZeneca amounted to 5.0 percent of the votes and capital. In a statement, Investor President and CEO Marcus Wallenberg said: "We have decided to reduce our leverage and strengthen our financial flexibility. We continue to believe strongly in AstraZeneca and the company is still our largest holding." INVESTOR AB For further information: Fredrik Lindgren, Vice President, Corporate Communications: +46 8 614 20 31, +46 735 24 20 31 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/02/11/20040211BIT00350/wkr0001.doc http://www.waymaker.net/bitonline/2004/02/11/20040211BIT00350/wkr0002.pdf

About Us

Investor is the leading owner of Nordic-based international companies, founded by the Wallenberg family a hundred years ago. We own significant minority or majority interests in high quality companies. Through our participation on the boards of directors, we work for continuous improvement of the performance of the companies. With our industrial experience, network and financial strength we strive to make our companies best-in-class. Our cash flow allows us to support strategic initiatives in our companies, capture investment opportunities and provide our shareholders with a dividend. Our Core Investments include listed holdings Atlas Copco, SEB, ABB, Ericsson and the operating subsidiary Mölnlycke Health Care.

Subscribe